Vir Biotechnology is a biotechnology business based in the US. Vir Biotechnology shares (VIR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.89 – an increase of 7.49% over the previous week. Vir Biotechnology employs 587 staff and has a trailing 12-month revenue of around $78.6 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $7.89 |
|---|---|
| 52-week range | $6.56 - $13.09 |
| 50-day moving average | $7.98 |
| 200-day moving average | $8.78 |
| Wall St. target price | $29.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-3.93 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.95 from 2025-01-06
| 1 week (2024-12-31) | 8.31% |
|---|---|
| 1 month (2024-12-06) | -4.79% |
| 3 months (2024-10-08) | 8.61% |
| 6 months (2024-07-08) | -5.69% |
| 1 year (2024-01-08) | -23.04% |
|---|---|
| 2 years (2023-01-06) | -69.48% |
| 3 years (2022-01-07) | 33.63 |
| 5 years (2020-01-08) | 12.43 |
| Revenue TTM | $78.6 million |
|---|---|
| Gross profit TTM | $1 billion |
| Return on assets TTM | -19.41% |
| Return on equity TTM | -36.58% |
| Profit margin | 0% |
| Book value | $9.08 |
| Market Capitalization | $1 billion |
TTM: trailing 12 months
We're not expecting Vir Biotechnology to pay a dividend over the next 12 months.
Over the last 12 months, Vir Biotechnology's shares have ranged in value from as little as $6.56 up to $13.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vir Biotechnology's is 0.457. This would suggest that Vir Biotechnology's shares are less volatile than average (for this exchange).
Vir Biotechnology, Inc. , an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. ; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd. ; and a collaborative research agreement with GlaxoSmithKline Biologicals S.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Access remote advice, planning and portfolio management from this established financial services company.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.